Susquehanna Fundamental Investments’s Adaptimmune Therapeutics ADAP Stock Holding History

Susquehanna Fundamental Investments’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-43,960	Closed	-$227K	–	1405
2021 Q3	$227K	Sell	43,960 -75,790	-63%	-$340K	﹤0.01%	1497
2021 Q2	$510K	Sell	119,750 -39,940	-25%	-$194K	0.01%	1157
2021 Q1	$848K	Sell	159,690 -12,060	-7%	-$69K	0.01%	951
2020 Q4	$926K	Buy	171,750 +68,415	+66%	+$372K	0.02%	888
2020 Q3	$825K	Buy	103,335 +39,135	+61%	+$342K	0.02%	707
2020 Q2	$643K	Buy	+64,200	New	+$403K	0.03%	545

Other funds holding ADAP

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Susquehanna Fundamental Investments's ADAP Position: Q4 2021 in Review

Susquehanna Fundamental Investments sold out of Adaptimmune Therapeutics (ADAP) in Q4 2021, closing a stake of 43,960 shares — an estimated $227K sold.

Susquehanna Fundamental Investments first reported a position in ADAP in Q2 2020 and held it in 6 quarters. The position peaked at $926K in Q4 2020. 85 funds tracked by Wall St. Rank hold ADAP as of Q4 2021.

Susquehanna Fundamental Investments reported no remaining Adaptimmune Therapeutics position as of Q4 2021 after selling out during the quarter.
Susquehanna Fundamental Investments sold 43,960 Adaptimmune Therapeutics shares in Q4 2021, an estimated $227K.
Susquehanna Fundamental Investments first reported a position in Adaptimmune Therapeutics in Q2 2020 and held it in 6 quarters.
Susquehanna Fundamental Investments's Adaptimmune Therapeutics position peaked at $926K in Q4 2020.
85 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2021.

Based on Susquehanna Fundamental Investments's 13F filing for Q4 2021, filed 14 Feb 2022.